Genomic Profiling with MammaPrint® + BluePrint® Identifies Aggressive Tumor Subtypes Driving Racial Survival Disparities in HR+/HER2– Early-Stage Breast Cancer

Study of over 1000 females with breast cancer finds that genomic risk and molecular subtype, and not race, drives ...

Health Rounds: Genetic testing improves treatment, survival for Black breast cancer patients

(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays.) By ...
ascopubs.org

Expression Profile–Defined Classification of Lung Adenocarcinoma Shows Close Relationship With Underlying Major Genetic Changes and Clinicopathologic Behaviors

Multicenter Phase I Study of Repeated Intratumoral Delivery of Adenoviral p53 in Patients With Advanced Non–Small-Cell Lung Cancer This study successfully established a basis for expression ...
European Medical Journal

Integrated Genomic Model Improves CAD Risk Prediction

Although the integrated genomic model provided only modest improvements over polygenic risk scores at a population level, its ...
ascopubs.org

Correlation of urinary comprehensive genomic profile with risk of recurrence of BCG-unresponsive non-muscle invasive bladder cancer treated with atezolizumab in SWOG S1605.

Estimating the impact of adjuvant treatment with nivolumab on long-term survivorship rates compared with surveillance: Analyses of disease-free survival (DFS) from the phase 3 CheckMate-274 trial.

Agendia, Inc.: Genomic Profiling with MammaPrint + BluePrint Identifies Aggressive Tumor Subtypes Driving Racial Survival Disparities in HR+/HER2- Early-Stage Breast Cancer

Multicenter study of over 1000 females with breast cancer, published in npj Breast Cancer, finds that genomic risk and molecular subtype, and not race, drives differential survival outcomes Agendia ...